You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient, tumor and treatment characteristics

From: Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results

  n n% Mean (min.-max.)
Age    68 (48–80)
Fup (months)    23 (9–47)
TNM T1cN0 31 62%  
T2aN0 17 34%  
T2bN0 1 4%  
T2cN0 1 2%  
Gleason 3+3 41 82%  
3+4 9 18%  
IPSA     8.2 (1.3–16)
Prostate volume     48 (22–110)
Q-max     13 (4–33)
Residual     87 (0–300)
Risk Group Low risk 30 60%  
Intermediate risk 20 40%  
Position positive biopsy Single sided 31 62%  
Double sided 19 38%  
Count positive biopsy 1 12 24%  
2 14 28%  
3 9 18%  
4 8 16%  
5 5 10%  
  7 2 4%